Search Results - "Ackaert, Oliver"

Bioequivalence clinical trial simulation: a case study of apalutamide administered in applesauce versus whole tablets by Yu, Alex, Ackaert, Oliver

“…Patients who have difficulty swallowing apalutamide tablets may benefit from administration in a food vehicle that is easier to swallow. In a previous…”
Get full text

Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics by McCormack, Clare P, Goethals, Olivia, Goeyvaerts, Nele, Woot de Trixhe, Xavier D, Geluykens, Peggy, Borrenberghs, Doortje, Ferguson, Neil M, Ackaert, Oliver, Dorigatti, Ilaria

“…Dengue virus (DENV) is a public health challenge across the tropics and subtropics. Currently, there is no licensed prophylactic or antiviral treatment for…”
Get full text

Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study by T’jollyn, Huybrecht, Ackaert, Oliver, Chien, Caly, Lopez-Gitlitz, Angela, McCarthy, Sharon, Ruixo, Carlos Perez, Karsh, Lawrence, Chi, Kim, Chowdhury, Simon, Ruixo, Juan-Jose Perez, Agarwal, Neeraj

“…Purpose Apalutamide plus androgen-deprivation therapy (ADT) has been approved for treatment of patients with metastatic castration-sensitive prostate cancer…”
Get full text

Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects by Pérez-Ruixo, Carlos, Pérez-Blanco, Jonás Samuel, Chien, Caly, Yu, Margaret, Ouellet, Daniele, Pérez-Ruixo, Juan-José, Ackaert, Oliver

“…Background Apalutamide is a next-generation androgen receptor inhibitor approved for treatment of subjects with high-risk, non-metastatic, castration-resistant…”
Get full text

Model‐based meta‐analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B‐infected mice by Sandra, Louis, T'jollyn, Huybrecht, Vermeulen, An, Ackaert, Oliver, Perez‐Ruixo, Juan‐Jose

“…The objective of this study was to compare the efficacy of short interfering RNA therapeutics (siRNAs) in reducing hepatitis B surface antigen (HBsAg) levels…”
Get full text

JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OMEGA‐1 by Zeuzem, Stefan, Bourgeois, Stefan, Greenbloom, Susan, Buti, Maria, Aghemo, Alessio, Lampertico, Pietro, Janczewska, Ewa, Lim, Seng Gee, Moreno, Christophe, Buggisch, Peter, Tam, Edward, Corbett, Chris, Willems, Wouter, Vijgen, Leen, Fevery, Bart, Ouwerkerk‐Mahadevan, Sivi, Ackaert, Oliver, Beumont, Maria, Kalmeijer, Ronald, Sinha, Rekha, Biermer, Michael

“…The combination of three direct‐acting antiviral agents (AL‐335, odalasvir, and simeprevir: JNJ‐4178 regimen) for 6 or 8 weeks demonstrated good efficacy and…”
Get full text

Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation by TEN BRINK, Marloes H, ACKAERT, Oliver, ZWAVELING, Juliëtte, BREDIUS, Robbert G. M, SMIERS, Frans J, DEN HARTIGH, Jan, LANKESTER, Arjan C, GUCHELAAR, Henk-Jan

“…High-dose treosulfan is used in conditioning regimens before hematopoietic stem cell transplantation in children. Pharmacokinetic data to optimize treosulfan…”
Get full text

Mechanistic studies of the transdermal iontophoretic delivery of 5-OH-DPAT in vitro by Ackaert, Oliver W, Van Smeden, Jeroen, De Graan, Jeroen, Dijkstra, Durk, Danhof, Meindert, Bouwstra, Joke A

“…A characterization and optimization of the in vitro transdermal iontophoretic transport of 5-hydroxy-2-(N,N,-di-n-propylamino)tetralin (5-OH-DPAT) is…”
Get more information

The pharmacokinetics and pharmacological effect of (S)-5-OH-DPAT following controlled delivery with transdermal iontophoresis by Ackaert, Oliver W, De Graan, Jeroen, Shi, Shanna, Vreeken, Rob, Pasqua, Oscar E Della, Dijkstra, Durk, Westerink, Ben H, Danhof, Meindert, Bouwstra, Joke A

“…The pharmacokinetic (PK) and pharmacodynamic (PD) properties of the active (S)-enantiomer of the potent dopamine (DA) agonist…”
Get more information

Transdermal iontophoretic delivery of a novel series of dopamine agonists in vitro: physicochemical considerations by Ackaert, Oliver W., De Graan, Jeroen, Capancioni, Romano, Dijkstra, Durk, Danhof, Meindert, Bouwstra, Joke A.

“…Objectives The transdermal iontophoretic delivery of a novel series of 2‐ aminotetralins and chromanamine‐based dopamine agonists was investigated in vitro…”
Get full text

The AAPS Journal Theme Issue: “Perspectives on Clinical Drug Development of Long-Acting Injectables” by T’jollyn, Huybrecht, Ackaert, Oliver

Get full text

Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers by Ackaert, Oliver, Vanhoutte, Frédéric, Verpoorten, Nathalie, Buelens, Annemie, Lachau-Durand, Sophie, Lammens, Lieve, Hoetelmans, Richard, Van Loock, Marnix, Herrera-Taracena, Guillermo

“…Abstract Background Dengue is a growing global health threat with no specific antiviral drugs available for treatment or prophylaxis. This first-in-human,…”
Get full text

Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics by Clare P. McCormack, Olivia Goethals, Nele Goeyvaerts, Xavier D. Woot de Trixhe, Peggy Geluykens, Doortje Borrenberghs, Neil M. Ferguson, Oliver Ackaert, Ilaria Dorigatti

Get full text

Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II) by T’jollyn, Huybrecht, Venkatasubramanian, Raja, Neyens, Martine, Gopal, Srihari, Russu, Alberto, Nandy, Partha, Perez-Ruixo, Juan Jose, Ackaert, Oliver

“…Background and Objective Paliperidone palmitate 6-month (PP6M) intramuscular (IM) injection is the longest-acting treatment available for patients with…”
Get full text

Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer by Perez-Ruixo, Carlos, Ackaert, Oliver, Ouellet, Daniele, Chien, Caly, Uemura, Hiroji, Olmos, David, Mainwaring, Paul, Lee, Ji Youl, Yu, Margaret K, Perez-Ruixo, Juan Jose, Smith, Matthew R, Small, Eric J

“…To evaluate the relationship between exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, and selected clinical efficacy and safety…”
Get full text

Understanding the dynamics of HBsAg decline through model-informed drug development (MIDD) of JNJ-3989 and JNJ-6379 for the treatment of chronic hepatitis B virus infection (CHB) by T’jollyn, Huybrecht, Goeyvaerts, Nele, Kakuda, Thomas, Sandra, Louis, Ogawa, Tetsuro, Vandenbossche, Joris J, de Trixhe, Xavier Woot, Lenz, Oliver, Kalmeijer, Ronald, Biermer, Michael, Perez Ruixo, Juan Jose, Ackaert, Oliver

Get full text

Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I) by T’jollyn, Huybrecht, Russu, Alberto, Venkatasubramanian, Raja, Gopal, Srihari, Nandy, Partha, Neyens, Martine, Faelens, Ruben, Samtani, Mahesh N., Ackaert, Oliver, Perez-Ruixo, Juan Jose

“…Background and Objective A model-informed drug development (MIDD) approach was implemented for paliperidone palmitate (PP) 6-month (PP6M) clinical development,…”
Get full text

Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates by Goethals, Olivia, Kaptein, Suzanne J. F., Kesteleyn, Bart, Bonfanti, Jean-François, Van Wesenbeeck, Liesbeth, Bardiot, Dorothée, Verschoor, Ernst J., Verstrepen, Babs E., Fagrouch, Zahra, Putnak, J. Robert, Kiemel, Dominik, Ackaert, Oliver, Straetemans, Roel, Lachau-Durand, Sophie, Geluykens, Peggy, Crabbe, Marjolein, Thys, Kim, Stoops, Bart, Lenz, Oliver, Tambuyzer, Lotke, De Meyer, Sandra, Dallmeier, Kai, McCracken, Michael K., Gromowski, Gregory D., Rutvisuttinunt, Wiriya, Jarman, Richard G., Karasavvas, Nicos, Touret, Franck, Querat, Gilles, de Lamballerie, Xavier, Chatel-Chaix, Laurent, Milligan, Gregg N., Beasley, David W. C., Bourne, Nigel, Barrett, Alan D. T., Marchand, Arnaud, Jonckers, Tim H. M., Raboisson, Pierre, Simmen, Kenny, Chaltin, Patrick, Bartenschlager, Ralf, Bogers, Willy M., Neyts, Johan, Van Loock, Marnix

“…Dengue is a major health threat and the number of symptomatic infections caused by the four dengue serotypes is estimated to be 96 million 1 with annually…”
Get full text

Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies) by Ackaert, Oliver, McDougall, David, Pérez-Ruixo, Carlos, Pérez-Ruixo, Juan Jose, Jezorwski, John, Crauwels, Herta M.

“…The single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg has undergone phase III studies AMBER…”
Get full text

Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir by Valade, Elodie, Kakuda, Thomas N., McClure, Matthew W., Westland, Christopher, Valenzuela, Belén, Ouwerkerk-Mahadevan, Sivi, Perez-Ruixo, Juan José, Ackaert, Oliver

“…The aim of the current study was to characterize the time course of plasma concentrations of AL-335 and its main metabolites (ALS-022399 and ALS-022227) after…”
Get full text